Malaysia Debt Ventures Berhad (578113-A)
The Nation’s Leading Technology Financier
MOSTI

IJN Uses Cutting-Edge Technology To Treat Congestive Heart Failure

KUALA LUMPUR, Jan 23 (Bernama) — The National Heart Institute (IJN) expects to use its latest cutting-edge Mardil VenTouch device on more patients who are at high risk of conventional surgery as the procedure has been proven to be safe.

“Patients who are at high risk of surgery are able to tolerate the therapy without any side effects,” said IJN Chief Executive Officer Tan Sri Dr Robaayah Zambahari.

Two patients, suffering from serious congestive heart failure and leaking mitral valve, were successfully operated to implant the device on Jan 21.

“The surgeries demonstrated that the procedure is safe, efficient and saves time. The first surgery took five hours but the second was done in two-and-a-half hours, actually it only takes about 45 minutes,” she told a press conference here Thursday.

Conventional surgeries cost between RM30,000 and RM40,000 while this procedure was expected to cost much more, she said, adding that patients with heart failure and leaking mitral valve conditions formed a subset of patients that were underserved by the current conventional treatment.

He said the institute would be able to apply this innovation for the benefit of patients after being chosen by Mardil Medical Incorporated, a US-based medical device company, to have access to the therapy.

“Malaysian Innovation Agency (AIM) invested US$5 million in the company, which developed the technology, and IJN became the only centre in the Asia Pacific region to have access to it.

“Chosen to be the “First-In-Man” centre after careful worldwide selection by Mardil Medical is testimony of IJN’s high standard of clinical expertise and its state-of-the-art facilities,” said its AIM Chief Executive Officer Mark Rozario.

He said an memorandum of understanding was signed in 2013 which allows for collaboration between both AIM and IJN for the creation of the Asian Centre of Excellence for clinical and product platform development of the “VenTouch Targeted Ventricular Reshaping System”.

“IJN and Mardil will be able to leverage on their clinical experiences to establish Asia’s first VenTouch implant procedure training centre, to train physicians across Asia,” he added.

— BERNAMA

Best viewed with Internet Explorer 7.0, Firefox 1.5 and Flash Player 8 and above.
© 2013 Malaysia Debt Ventures Berhad. All rights reserved. Please read our Disclaimer